

Non-HIV Related Non-Communicable Diseases in HIV Patients

Alisha S. Dhiman^{1*}, Jayesh Dwivedi¹, Renuka P. Munshi²

ABSTRACT

Authors examined the impact of additional factors on fatalities in Chronic HIV patient populations and should have remained on highly active antiretroviral therapy (HAART) for the at least 1 year: Inadequate response to HAART and the existence of AIDS-defining illnesses, depression, and drug and alcohol abuse, and especially in comparison the fatalities to that of the overall demographic. The enhanced rates of mortality in HIV-infected people are primarily impact on risk variables that can be recognized just before to or during the introductory phase of antiretroviral treatment. The fatality rate in patient populations without risk variables who are on effective HAART is virtually identical to something like the non-HIV-infected inhabitants. The significance of a holistic solution for lipid accumulation, cardiovascular, and glomerular comorbidity supervisors in the lengthy effective monitoring of chronic HIV old patients cannot be exaggerated.

Keywords: ART, Co-morbidity, HAART, HIV, Mortality, NCD, PLHIV, Risk variables

Asian Pac. J. Health Sci., (2022); DOI: 10.21276/apjhs.2022.9.1.21

INTRODUCTION

Inside the epoch of highly active antiretroviral therapy (HAART), death rate has declined substantially between many HIV-infected people who have access to HAART; however, there are worries about comorbidities and negative impacts of HAART, which may affect vital prognostic value. Mortality and burden of disease correlations in HIV-infected people receiving antiretroviral treatment are constantly changing due of immunologic regeneration and improved ability to survive. According to the ANGWENYI, AANTJES, and LAZARUS, in the HIV Cohort Study, authors have investigated the impact of ageing on the epidemiological data of non-AIDS ailments. The pervasive use of combination antiretroviral treatment has substantially extending the life average lifespan of chronic.

LITERATURE REVIEW

Role of Antiretroviral Therapy (ART)

HIV infection has become a chronic medical problem as a consequence of ART.^[1,2] People living with HIV (PLHIV) now have a mortality rate that is comparable to that of the regular populace. As a result, PLHIV are living longer lives and necessitating lifelong care and treatment. The percentage of proportion of people living with HIV who are over the age of 50 is expected to rise to 73% in 2030. Due to the substantial reduction in HIV/AIDS-related mortality, often well PLHIV have a lower life expectancy than people without HIV.

HIV/AIDS-related incidents continue to be high in the 1st year following HIV diagnosis, predominantly between premature delegates. However, for the 1st year of ART, non-communicable diseases are responsible of premature mortality.^[3] Infection has been identified as the main cause advancing age and may be a risk factor for non-communicable diseases (NCDs). The presence of NCDs in PLHIV may be comparable to that seen in Aids people 10 years older. Antiretroviral medications also have been associated with the expansion of cardiovascular disease (CVD), diabetes, bone loss, and hepatotoxicity.^[4]

¹Pacific College of Pharmacy, Pacific Academy of Higher Education and Research University, Udaipur, Rajasthan, India

²Department of Clinical Pharmacology, TN Medical College and BYL Nair Hospital, Mumbai, Maharashtra, India

Corresponding Author: Alisha S. Dhiman, Pacific College of Pharmacy, Pacific Academy of Higher Education and Research University, Udaipur, Rajasthan, India. E-mail: aldhiman19@gmail.com

How to cite this article: Dhiman AS, Dwivedi J, Munshi RP. Non-HIV Related Non-Communicable Diseases in HIV Patients. *Asian Pac. J. Health Sci.*, 2022;9(1):191-195.

Source of support: Nil

Conflicts of interest: None.

Received: 17/09/21 **Revised:** 18/10/21 **Accepted:** 02/11/21

Comorbidity on the Emergence in the HIV Context

According to the Ambrosioni *et al.* (2019), HIV/NCD comorbidity is becoming more and more common as people live longer with HIV in countries with a high HIV burden that are undergoing rapid urbanization and etiological transition. HIV-infected people have a higher risk of NCDs than HIV-uninfected people, due in part to HIV infection and the side effects of lengthy ravidly anti-therapy. Cardiovascular occurrences, osteoporosis, hypertension, nephritis, diabetes mellitus, and feelings of hopelessness and neuropsychiatric disorders are among the NCDs that are more commonly reported in HIV-infected people than in uninfected individuals.^[5,6] Aids children and teens, marked by high HIV viremia, have higher total cholesterol and lipids as well as higher surrogate markers of arterial stiffness than Aids, non-immune youths. Although methodical NCD checking is not lawfully merged into HIV prevention for adolescents, broad sense health checks and facility tests are developed to assess biological risk factors.^[7,8]

Effect of NCD in HIV Population

Due to the advent of neurocognitive signs, HIV infects the central nervous system (CNS), exacerbating neuronal loses.^[9] Diseased mitochondria in the CNS are assumed to publish inflammatory cytokines and neurotransmitters, further disrupting the

blood-brain hindrance. This encourages incursions by raising the size of eosinophils, which may be directly to blame for toxicities and the growth of Aids neuropsychiatric illness.^[10,11] The idea that HIV-infected people age quicker than the local public also has been suggested as a possible explanation for the high likelihood in that population.

Logerot *et al.* (2018) stated that immunotherapy, anti-retroviral potency, HIV-related inflammation, and ultimately require are the pattern cause underpinning of these non-communicable diseases in the HIV community. Metabolic abnormalities have been reported to be higher and occur at a younger age in people living with HIV than in Disease control participants in studies. Acute kidney illness have overtaken pathogenic organisms as the leading form of chronic burden of disease in HIV-positive patients because since this same intro of ART.^[12,13]

A Novel Treatment Model for Non-Communicable Disease

Incorporating medical services has the capability to minimize wait times by making good utilization of resources. The participation time of the advisor has a direct effect on the child's waiting time, particularly for the first appointment in both the morning and evening meetings. Trying to encourage patients through a new model is difficult, but it appears to do is provide substantial believable benefits in rural, resource-limited healthcare setting other than those supplied by rudimentary clinic services. An actual data comparisons showed that waiting times. Within a week of inclusion, the time was reduced by 7.2–3 h ($P < 0.01$) with clinic patients' participation improved noticeably.^[14,15]

MATERIALS AND METHODS

Materials

Study setting, patient population, and outcome

According to Kumi *et al.* (2018), researchers anticipated the percentage of PLWH with hypertension and bad cholesterol using a modified CVD risk prediction model (Globorisk) to evaluate the multiyear risk of atherosclerotic vascular disease using personal information on cardiometabolic risk factors, populace statistics on HIV prevalence and ART media attention, and the influence of HIV on hyperlipidemia. Furthermore, many models fail to account for the real impact of HIV on CVD, which is self-reliant of changes in the risk factors such as blood pressure, diabetes, and bad cholesterol. Apart from this effect could lead to an underestimation of CVD risk between many HIV-infected people. This contrast was based on assumptions made using the Cohort Study and the American Heart Association's pooled cohort threat scores, neither of which included this direct effect.^[16,17]

Methods

Various parts PF research methodology are described below

Research philosophy

There are four types of research philosophy in use depending on the nature of the study such as pragmatism, positivism, realism, and interpretivism. These research methods are chosen based on the practical implications of the study. To achieve the study's goal,

positivism research philosophy was used in this study. Positivism is a research philosophy that is involved in data collection and focuses on verifiable knowledge. Source and nature of the study are maintained with the help of this philosophy, due to this factor this philosophy has been selected.

Research design

Overall strategy and structure of research are maintained by research design, research design is classified into various categories. Among all categories descriptive research design has been selected by researcher. The based on the research objective because it is quick, simple, and inexpensive to carry out. With the use of a descriptive research design, a large volume of data is captured. The neuroscientist must obtain intelligence about the aims and purpose of the research. Primary data were gathered from a variety of sources, including surveys, interviews, and other important sources. Interviewees include journalists and employees from online news publications. Secondary data are also employed. Here secondary data are primarily concerned.^[18,19]

Research approach

Hypothesis of research is maintained by research approach. The types of research approaches that can be used in the study are mixed method. Research approach has two types such as inductive and deductive research approach. A deductive method is included in this research project. Deductive methodologies assist researchers in collecting data efficiently, increasing the likelihood of finalizing the objective of this study and creating the experiment more accurate.^[20]

Data Collection and Data Analysis

The precision of investigation is maintained through the use of a proper and efficient acquisition cycle. Researchers' mindsets and experiences are indeed aided by this process. Primary and secondary data are used in research; however, this study is conducted using secondary data. Interviews, surveys, online communities, and other raw data collection processes are often used to collect primary data. A survey questionnaire chart is also used to collect primary data. Secondary data, on the other hand, were gathered from research papers on an awarded proposed study, journals, books, websites, newspapers, and others. This study's secondary data collection process can save time and money. The use of secondary data also helps to maintain the research's authenticity. The study performed at least 20 journal articles to gather accurate information about this particular research.^[21,22]

Data Sampling

Data sampling is a probabilistic analysis technique that selects, manipulates, and analyses a sufficient to establish of data sets to pinpoint patterns and forecasts in the larger data set under consideration. Simple random sampling is one of the most basic methods of gathering information from the entire populace. Each member of the subcategory has an equal probability of being chosen as part of the sample selection process in the form of random sampling. For drawing observations, an unbiased random sample is required.^[23-25]

RESULTS AND DISCUSSION

Socio Demographic Profiles

The average age of the respondents was 36 years, with the majority of them being between the ages of 28 and 37 ($n = 56, 37.3\%$). About

78% of the participants were engaged, with the majority being traders ($n = 37, 24.7\%$) and wedded ($n = 65, 43.3\%$). The majority (88%) lived with others such as partners, kids, and so on, while 18 (12%) lived alone. In the month preceding the study, 90 participants (60%) were interested in sex, and 40 (27%) engaged in unsafe intercourse, some with multiple sexual partners (7.5%). From Table 1, some demographic factors are shown for prediction [Figure 1].^[26,27]

Chart on HIV Infections

The chart of HIV type 1 virus was found in and between 145 (94%) of respondents, to 65 (42%) of all attendees in Stage 1 of the infection. The majority of them ($n = 78; 52\%$) had been HIV positive for at least 13–36 months, and 66 (44%) had a sex partner who was still HIV positive, while 135 (90%) were on antiretroviral drugs.




Figure 1: Conceptual model discussion on several observation for HIV ART attrition. ART: Antiretroviral therapy. (Source: Jespersen et al., 2021, p. 213)




Figure 2: P-value ranges in causable areas. (Source: Kirchherr and Charles, 2018 p. 321)

According to HIV infections rate the comorbidity is also sometimes correlated with patients have more than one condition. Figure 2 shows the result of p-value in the above sampling cases.^[28]

From Figure 3, over 2500 patients who received a multi-drug ART regimen at the hospital sites were included in the study cohort. The paper distinguishes approximately 115 pediatric patients, 15 patients of indeterminate gender, and 1 patient of unknown gender. Overall, 35% of patients fulfilled the 30+ day community pharmacies attrition definition, 17% fulfilled the 60+ day pharmacy attrition definition, 48% fulfilled the 90+ day occurrence definition, and 16% fulfilled the 180+ day occurrence definition. Only a comparatively slight number of patients who managed to stop receiving medical care at the sites were transferred to another facility in a timely manner.^[29]

Even under meanings, attrition climbed rapidly all through the first 12 months since ART inception, with 27% of patients giving up ART there under 30+ day pharmacy definition (95% confidence interval). Whereas attrition in the 30 plus day pharmacy definition decreased significantly after 12 months, it enhanced more steadily in the 90 plus day occurrence definition over time. At each time point, attrition under the 60 plus day community pharmacies definition was roughly half that under the 30 plus day pharmacy description. This suggests that a significant portion of attrition was due to temporary interruptions in care. Attrition rates were comparable under the 60+ day community pharmacies definition and the 180+ occurrence definition.

Folorunso et al. (2021) stated that, when clinically indicated domiciled in almost the same communist utopia as the clinic, adjusted ART high turnover risk was 69% higher for patients residing in an adjacent communist utopia (Hazard ratio: 1.7, $P < 0.001$) and 89% higher for patient populations residing in a non-adjacent communist utopia (HR: 1.9, $P < 0.001$). The modified model revealed an attrition hazard that reduced with the process time of ART start ($P < 0.001$). In the modified assessment, obtaining a low duration of enlistment in HIV care before ART initiation ($P < 0.01$), a non-standard ART exercise regime ($P < 0.05$), no counseling weekly sessions leading up to ART initiation ($P < 0.10$), and a body mass index (BMI) > 18.5 ($P < 0.10$) were also linked to higher high turnover hazard [Table 2].

DISCUSSION

According to the findings, respondents with diagnosable pathogens were more likely to have suicidal thoughts.^[30,31] The existence of these infections increases the morbidity and suffering encountered by these patients and may explain why they have so much thoughts of suicide. Even though earlier studies did not specifically target comorbid infections, they did find an increase in suicidality among HIV patients with comorbid disorders. Suicidal thoughts were most common in younger age patients. These have initially been

Table 1: Measurement and non-measurement parameters of several factors associated with attrition

List of factors	Measured parameters	Unmeasured parameters
Patient demographic factors	Age, gender, proximity of residence	Socioeconomic position, occupation, education
Patient clinical factors	Age, gender, proximity of residence	BMI, WHO stage, ART regimen, symptoms (WHO Stage IV)
Co-morbidity Supervising	Multi disease, Multiorgan analysis	Past Non-HIV diseases
Environmental or weather Factors	Any climate condition, that is, earthquake, flood and weather change	About land profile

ART: Antiretroviral therapy




Figure 3: Conceptual ART attrition estimates. ART: Antiretroviral therapy. (Source: Jespersen *et al.*, 2021, p. 652)

Table 2: Distribution of average some cause variables for the HIV/AIDS patient

Variable	P-value
Smoking	<0.067
Other comorbidities and polypharmacy	<0.001
Hepatitis B	<0.580
AIDS-defining illness	<0.001

described that young people, with exception of older people, are just beginning out in life with a lot of pride and desires.^[32,33]

Jespersen *et al.* (2019), even after adjusting for period and conventional cardiovascular risk factors. HIV disease and antiretroviral treatment appear to be causation related with early heart disease. A few anti-retroviral therapy medications have a direct impact on cardiovascular. Continuous exposure to proteolytic enzymes, for instance, has been linked to with dyslipidemia, insulin sensitivity, and a greater BMI the frequency of heart disease events. Abacavir is a common nicotinamide alternative to increase the risk of heart disease possibly as a result of because of its procoagulant impact.^[34,35]

CONCLUSION

Optimized HIV recognition strategies are usually needed, especially in marginalized and susceptible populaces in country and its territories. Moreover, the preventative measures, testing, and strategic planning of non-lymphoma and non-AIDS-related diseases, as well as the management and mitigation of liver diseases, must be considered legitimate wellness preferences. Non-AIDS exacerbations, especially heart disease, bone loss, diabetes, and non-AIDS-defining diseases, become more prevalent in Aids people as they age. Aside from illness data analysis, research findings on comprehensive HIV care should fixate on shapes of sequential comorbidity and concurrent comorbidities. Because period is a quasi-factor, it is crucial to monitor for and inhibit age-related multifactorial risks of non-AIDS disorder.

RECOMMENDATION

The emphasis of the WHO's task to help stop NCD lives lost is on lowering the major risk factors for NCDs-cigarette use, physical inactivity, unhealthy lifestyle, and hazardous alcohol use. NCDs are

responsible for majorly heart and lung diseases, as well as kidney disease – are the world's leading causes of death, responsible for an approximate 38 million deaths each and every year. 16 million people die annually are untimely. NCD deterrence is becoming increasingly important because of the liability of NCDs falls primarily on poor especially in developing countries, in which 82% of premature deaths from these diseases arise.

REFERENCES

1. Abudan AA, Vaidya VR, Tripathi B, Noseworthy PA, DeSimone DC, Egbe A, *et al.* Burden of arrhythmia in hospitalized HIV patients. *Clin Cardiol* 2021;44:66-77.
2. Ackerman CM, Myhrvold C, Thakku SG, Freije CA, Metsky HC, Yang DK, *et al.* Massively multiplexed nucleic acid detection with Cas13. *Nature* 2020;582:277-82.
3. Akimbekov NS, Ortoski RA, Razzaque MS. Effects of sunlight exposure and Vitamin D supplementation on HIV patients. *J Steroid Biochem Mol Biol* 2020;200:105664.
4. Ambrosioni J, Rico JÁ, Nicolás D, Mosquera MM, de Lazzari E, Marcos M, *et al.* E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection, AIDS (London, England) 2019;33:1613-7.
5. Bandera A, Gori A, Clerici M, Sironi M. Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance. *Curr Opin Pharmacol* 2019;48:24-32.
6. Bender AM, Simonetti FR, Kumar MR, Fray EJ, Bruner KM, Timmons AE, *et al.* The landscape of persistent viral genomes in ART-treated SIV, SHIV, and HIV-2 infections. *Cell Host Microbe* 2019;26:73-85.e74.
7. Bender Ignacio R, Ghadrshenas M, Low D, Orem J, Casper C, Phipps W. HIV status and associated clinical characteristics among adult patients with cancer at the uganda cancer institute. *J Global Oncol* 2018;4:1-10.
8. Bertoldi A, D'Urbano V, Bon I, Verbon A, Rokx C, Boucher C, *et al.* Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1. *J Virol Methods* 2020;276:113778.
9. Blumberg EA, Rogers CC. Solid organ transplantation in the HIV-infected patient: Guidelines from the American society of transplantation infectious diseases community of practice. *Clin Transpl* 2019;33:e13499.
10. Cao Z, Li J, Chen H, Song C, Shen Z, Zhou X, *et al.* Effects of HIV-1 genotype on baseline CD4+ cell count and mortality before and after antiretroviral therapy. *Sci Rep* 2020;10:15875.
11. Castelli R, Schiavon R, Preti C, Ferraris L. HIV-related lymphoproliferative diseases in the era of combination antiretroviral therapy. *Cardiovasc Hematol Disord Drug Targets* 2020;20:175-80.
12. Chisati EM, Constantinou D, Lampiao F. Reduced bone mineral density among HIV infected patients on anti-retroviral therapy in Blantyre, Malawi: Prevalence and associated factors. *PLoS One* 2020;15:e0227893.
13. Dandachi D, Morón F. Effects of HIV on the tumor microenvironment. *Adv Exp Med Biol* 2020;1263:45-54.
14. Darcis G, Moutschen M. HIV cure: A realistic perspective?. *Rev Med Liege* 2017;72:388-92.
15. Delaney KP, Hanson DL, Masciotra S, Ethridge SF, Wesolowski L, Owen SM. Time until emergence of HIV test reactivity following infection with HIV-1: Implications for interpreting test results and retesting after exposure. *Clin Infect Dis* 2017;64:53-9.
16. den Daas C, van den Berk GE, Kleene MT, de Munnik ES, Lijmer JG, Brinkman K. Health-related quality of life among adult HIV positive patients: Assessing comprehensive themes and interrelated associations, Quality of life research. *Int J Quality Life Aspects Treat Care Rehabil* 2019;28:2685-94.
17. Deng H, Deng X, Liu Y, Xu Y, Lan Y, Gao M, *et al.* Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or

- co-infected with HBV or HCV in China. *J Med Virol* 2018;90:1246-56.
18. Engelman AN, Singh PK. Cellular and molecular mechanisms of HIV-1 integration targeting. *Cell Mol Life Sci* 2018;75:2491-507.
 19. Fujinaga K, Cary DC. Experimental systems for measuring HIV latency and reactivation. *Viruses* 2020;12:1279.
 20. Ganor Y, Real F, Sennepin A, Dutertre CA, Prevedel L, Xu L, *et al.* HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy. *Nat Microbiol* 2019;4:633-44.
 21. Gavrilova TV, Shmagel NG, Chereshneva MV, Sergienko AP, Ivanova ES, Chereshnev VA. Ocular lesions in HIV-infected patients of the ophthalmic hospitals. *Vestnik Oftalmol* 2018;134:25-32.
 22. Grassi L, Caruso R, Costantini A. Communication with patients suffering from serious physical illness. *Adv Psychosom Med* 2015;34:10-23.
 23. Guedes DL, Medeiros Z, Dionísio da Silva E, Martins de Vasconcelos AV, Santana da Silva M, Lopes da Silva MA, *et al.* Visceral leishmaniasis in hospitalized HIV-infected patients in pernambuco, Brazil. *Am J Trop Med Hyg* 2018;99:1541-6.
 24. Hizi A, Herzig E. dUTPase: The frequently overlooked enzyme encoded by many retroviruses. *Retrovirology* 2015;12:70.
 25. Jespersen S, Tolstrup M, Hønge BL, Medina C, Ellermann-Eriksen S, Østergaard L, *et al.* High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau. *Virol J* 2015;12:41.
 26. Jiang Y, Chai L, Fasae MB, Bai Y. The role of HIV Tat protein in HIV-related cardiovascular diseases. *J Transl Med* 2018;16:121.
 27. Jilg N, Li JZ. On the road to a HIV cure: Moving beyond Berlin and London. *Infect Dis Clin North Am* 2019;33:857-68.
 28. Komziuk AT, Velichko DM, Goshovsky VS, Goshovska VA, Klymenko OV. The rights of surgeons while working with hiv-infected patients in Ukraine. *Wiadomosci Lekarskie* 2019;72:279-83.
 29. Koren DE, Scarsi KK, Farmer EK, Cha A, Adams JL, Pandit NS, *et al.* A call to action: The role of antiretroviral stewardship in inpatient practice, a joint policy paper of the infectious diseases society of America, HIV medicine association, and American academy of HIV medicine. *Clin Infect Dis* 2020;70:2241-6.
 30. Kumi Smith M, Jewell BL, Hallett TB, Cohen MS. Treatment of HIV for the prevention of transmission in discordant couples and at the population level. *Adv Exp Med Biol* 2018;1075:125-62.
 31. Lindman J, Hønge BL, Kjerulff B, Medina C, da Silva ZJ, Erikstrup C, *et al.* Performance of Bio-rad HIV-1/2 confirmatory assay in HIV-1, HIV-2 and HIV-1/2 dually reactive patients-comparison with INNO-LIA and immunocomb discriminatory assays. *J Virol Methods* 2019;268:42-7.
 32. Lo Presti A, Farcomeni S, Fontanelli Sulekova L, Grieco S, Sernicola L, Baesso M, *et al.* Characterization of HIV-1 subtypes among south sudanese patients. *AIDS Res Hum Retrov* 2019;35:968-71.
 33. Logerot S, Rancez M, Charmeteau-de Muylder B, Figueiredo-Morgado S, Rozlan S, Tambussi G, *et al.* HIV reservoir dynamics in HAART-treated poor immunological responder patients under IL-7 therapy. *AIDS (London, England)* 2018;32:715-20.
 34. Lorenzoni PJ, Ducci RD, Dalledone GO, Kay CS, de Almeida SM, Werneck LC, *et al.* Motor neuron disease in patients with HIV infection: Report of two cases and brief review of the literature. *Clin Neurol Neurosurg* 2018;171:139-42.
 35. Lucas S, Nelson AM. HIV and the spectrum of human disease. *J Pathol* 2015;235:229-41.